Literature DB >> 20954136

Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23.

Giorgio Coen1, Paolo De Paolis, Paola Ballanti, Andrea Pierantozzi, Stefania Pisanò, Daniela Sardella, Daniela Mantella, Luigi Pellegrino, Giuliana Silvestrini, Massimo Iappelli, Salvatore Di Giulio.   

Abstract

BACKGROUND: Calcification of arteries is a frequent occurrence in hemodialysis (HD) patients and is linked to mortality. This study was conducted to evaluate the correspondence between coronary calcification scores and calcifications observed histologically in peripheral arteries in HD patients. In addition the association of humoral parameters including fetuin-A and fibroblast growth factor 23 (FGF-23) with arterial calcifications was studied. PATIENTS AND METHODS: HD patients (n=44) were studied with multislice computed tomography (CT) and histological quantification of arterial calcifications in the lower epigastric artery sampled at the time of renal transplant. In addition, humoral assays were performed including fetuin-A and FGF-23.
RESULTS: There was a significant correlation between medial calcification of the artery and Agatston scores. Natural logarithm (Ln) FGF-23 significantly correlated to Ln Agatston score but not to Ln medial calcification. A significant negative correlation between fetuin-A and Ln FGF-23 was observed, changing to borderline significance after correction for age and Ln HD age. Ln Agatston score in a multiregression analysis was predicted by Ln FGF-23 and age.
CONCLUSIONS: The association found between histologically evaluated calcification of the media of a peripheral artery in HD and the multislice CT Agatston scores is in favor of a generalized arterial calcification, either intimal or of tunica media, when calcium deposits are found in the coronary arteries. The association of FGF-23 with coronary calcification score, already reported, and less so with histological medial calcification is in favor of a link between the protein and intimal more than the medial calcification. FGF-23 may be considered a potential biomarker of arterial calcification in HD patients. The negative association between fetuin-A and FGF-23 may suggest a linkage between these humoral substances, vascular calcifications and mortality. The nature of this linkage requires further studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20954136     DOI: 10.5301/JN.2010.5818

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  11 in total

1.  FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients.

Authors:  Diana Moldovan; Ioan Moldovan; Crina Rusu; Ina Kacso; Ioan Mihai Patiu; Mirela Gherman-Caprioara
Journal:  Int Urol Nephrol       Date:  2013-04-03       Impact factor: 2.370

2.  Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus.

Authors:  Barry I Freedman; Jasmin Divers; Gregory B Russell; Nicholette D Palmer; Donald W Bowden; J Jeffrey Carr; Lynne E Wagenknecht; R Caresse Hightower; Jianzhao Xu; Susan Carrie Smith; Carl D Langefeld; Keith A Hruska; Thomas C Register
Journal:  Am J Nephrol       Date:  2015-12-23       Impact factor: 3.754

Review 3.  Fibroblast growth factor 23 as a phosphotropic hormone and beyond.

Authors:  Seiji Fukumoto; Yuichiro Shimizu
Journal:  J Bone Miner Metab       Date:  2011-08-06       Impact factor: 2.626

4.  Coronary artery calcification is inversely related to body morphology in patients with significant coronary artery disease: a three-dimensional intravascular ultrasound study.

Authors:  George D Dangas; Akiko Maehara; Solene M Evrard; Samantha Sartori; Jennifer R Li; Amala P Chirumamilla; Aya Nomura-Kitabayashi; Nilusha Gukathasan; Ahmed Hassanin; Usman Baber; Martin Fahy; Valentin Fuster; Gary S Mintz; Jason C Kovacic
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2013-07-31       Impact factor: 6.875

Review 5.  Is fibroblast growth factor 23 a harbinger of mortality in CKD?

Authors:  Jason R Stubbs; Steve Egwuonwu
Journal:  Pediatr Nephrol       Date:  2011-03-10       Impact factor: 3.714

6.  FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.

Authors:  Neerupma Silswal; Chad D Touchberry; Dorothy R Daniel; Darla L McCarthy; Shiqin Zhang; Jon Andresen; Jason R Stubbs; Michael J Wacker
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-07-22       Impact factor: 4.310

7.  Diagnosis of Arterial Media Calcification in Chronic Kidney Disease.

Authors:  Annibale Marinelli; Valentina Pistolesi; Luciano Pasquale; Luca Di Lullo; Mariateresa Ferrazzano; Giuseppina Baudena; Franco Della Grotta; Anteo Di Napoli
Journal:  Cardiorenal Med       Date:  2013-04-18       Impact factor: 2.041

8.  Cardiovascular risk in chronic kidney disease patients: intima-media thickness predicts the incidence and severity of histologically assessed medial calcification in radial arteries.

Authors:  Katarzyna Janda; Marcin Krzanowski; Mariusz Gajda; Paulina Dumnicka; Danuta Fedak; Grzegorz J Lis; Piotr Jaśkowski; Agata Pietrzycka; Jan A Litwin; Władysław Sułowicz
Journal:  BMC Nephrol       Date:  2015-06-03       Impact factor: 2.388

9.  Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.

Authors:  Julia J Scialla; Wei Ling Lau; Muredach P Reilly; Tamara Isakova; Hsueh-Ying Yang; Matthew H Crouthamel; Nicholas W Chavkin; Mahboob Rahman; Patricia Wahl; Ansel P Amaral; Takayuki Hamano; Stephen R Master; Lisa Nessel; Boyang Chai; Dawei Xie; Radhakrishna R Kallem; Jing Chen; James P Lash; John W Kusek; Matthew J Budoff; Cecilia M Giachelli; Myles Wolf
Journal:  Kidney Int       Date:  2013-02-06       Impact factor: 10.612

Review 10.  Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.

Authors:  Anjay Rastogi
Journal:  Ther Adv Cardiovasc Dis       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.